Quality of life of patients with multiple sclerosis having different schemes of therapy
Comparative analysis of clinical severity measured by scales (EDSS, SCRIPSS) and quality of life (QL) parameters using MOS SF-36, QL-WHO questionnaires and psychometric scales (Chronic fatigue scale, Beka depression scale) was performed in patients with multiple sclerosis (MS) during 15 months of immunomodulating (Copaxone, rebif, betaferon), symptomatic (semax, aplegin) therapy and rehabilitation. Data of 219 cases with definite MS were analyzed. Control groups included 30 healthy volunteers and 64 patients with definite MS, who hadn't taken immunomodulating drugs. The comparative analysis showed that increase in EDSS score leads to significant deterioration of QL parameters in scales of physical health and emotional status which reflects the disease influence not only on physical problems but also on emotional sphere of patientfs life and is accompanied by disturbances in patientfs physical functioning which are related to deviations in patientfs psychological, emotional, mental, spiritual and social life